Insulet Corporation (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Insulet Corporation (NASDAQ:PODD) have earned a consensus rating of “Moderate Buy” from the twenty-seven ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and twenty-one have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $240.7826.

Several research firms have weighed in on PODD. Royal Bank Of Canada reiterated an “outperform” rating and issued a $280.00 price objective on shares of Insulet in a report on Wednesday, May 27th. Robert W. Baird dropped their target price on shares of Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Citigroup dropped their target price on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, May 28th. Barclays dropped their target price on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Finally, UBS Group set a $219.00 target price on shares of Insulet in a research report on Thursday, June 11th.

Insulet Stock Performance

NASDAQ PODD opened at $145.76 on Monday. Insulet has a fifty-two week low of $140.63 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The stock has a 50 day simple moving average of $164.18 and a two-hundred day simple moving average of $225.67. The stock has a market cap of $10.10 billion, a P/E ratio of 33.90, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter last year, the business posted $1.02 EPS. The business’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts forecast that Insulet will post 6.46 earnings per share for the current year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.36% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC lifted its stake in shares of Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Insulet in the 4th quarter valued at approximately $26,000. DV Equities LLC purchased a new position in shares of Insulet in the 4th quarter valued at approximately $28,000. Elyxium Wealth LLC purchased a new position in shares of Insulet in the 4th quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new position in shares of Insulet in the 4th quarter valued at approximately $29,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.